Hermes Medical Solutions Receives 510k Approval for Hybrid3D™ SIRT
Stockholm - October 26th 2018
Hermes Medical Solutions releases Hybrid3D™ SIRT, the only complete and consistent SIRT workflow: Dose Planning with Tc-99mMAA using FDA approved methods of Resin and Glass Microspheres and Dose Verification with Y90 Microspheres.
An intuitive end-to-end workflow takes the decision maker through both planning and verification. Hybrid3D™ SIRT continues the Hermes Medical Solutions standard of supporting vendor neutral clinical workflows.
Hermes Medical Solutions maintains its position as the only company capable of delivering quantitative SUV SPECT®, which is critical for confidence and improving speed to clinical decision.
To learn more about the new Hybrid 3D™ SIRT and how Hermes is bringing Innovation for Referring Services and Treatment, visit us at booth #4955 during the RSNA meeting November 25th through November 30th 2018.
About Hermes Medical Solutions
Hermes Medical Solutions holds more than 40 years of recognition for Clinical Excellence and innovation in Molecular Imaging. Hermes delivers Enterprise Class systems and software for integrating, visualizing, processing and archiving imaging data from different imaging modalities and devices within Molecular Imaging and Radiology. Hermes solutions are empowering physicians by enabling a faster and more accurate diagnosis of patients, thereby improving quality and efficiency for healthcare provider’s clinical decision making.
Director Strategic Marketing